Sarepta, gene therapy
Digest more
A filing with the state details the Columbus job cuts for a biotech cutting more than one-third of its workforce.
Sarepta Therapeutics has paused U.S. shipments of its gene therapy Elevidys after two teenagers with Duchenne muscular dystrophy died of liver failure. The suspension follows an FDA request and affects non-ambulatory patients.
Shares of Sarepta Therapeutics declined 17% in early trading on Friday after another patient who had received an experimental gene therapy died, deepening investor concerns over the use of the company's treatments.
Stocktwits on MSN2d
GlucoTrack, Sarepta, TNF Pharma Dominate Weekly Retail Health Care Buzz — Here’s WhyRetail chatter spiked last week as investors piled into three healthcare stocks: GlucoTrack, Sarepta Therapeutics, and TNF Pharmaceuticals, which recorded the highest increases in message volume among healthcare names on Stocktwits.
The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening financial situation.
On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.
Sarepta agrees to FDA's black box warning and announces major restructuring, including job cuts and cost-saving measures to meet 2027 goals.
Feedback